The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection

Murakawa, Masaaki; Aoyama, Toru; Miyagi, Yohei; Kobayashi, Satoshi; Ueno, Makoto; Morimoto, Manabu; Numata, Masakatsu; Yamamoto, Naoto; Tamagawa, Hiroshi; Yukawa, Norio; Rino, Yasushi; Masuda, Munetaka; Morinaga, Soichiro

doi:10.7150/jca.28660



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2019; 10(3):627-633. doi:10.7150/jca.28660 This issue Cite

Research Paper

The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection

Masaaki Murakawa^1✉, Toru Aoyama⁴, Yohei Miyagi², Satoshi Kobayashi³, Makoto Ueno³, Manabu Morimoto³, Masakatsu Numata⁴, Naoto Yamamoto¹, Hiroshi Tamagawa⁴, Norio Yukawa⁴, Yasushi Rino⁴, Munetaka Masuda⁴, Soichiro Morinaga¹

1. Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan
2. Molecular Pathology and Genetics Division, Kanagawa Cancer Center Research Institute
3. Department of Hepatobiliary Pancreatic Oncology, Kanagawa Cancer Center
4. Department of Surgery, Yokohama City University
Masaaki Murakawa and Toru Aoyama equally contributed this article.

Citation:

Murakawa M, Aoyama T, Miyagi Y, Kobayashi S, Ueno M, Morimoto M, Numata M, Yamamoto N, Tamagawa H, Yukawa N, Rino Y, Masuda M, Morinaga S. The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection. J Cancer 2019; 10(3):627-633. doi:10.7150/jca.28660. https://www.jcancer.org/v10p0627.htm

Other styles

Abstract

Background: The predictive roles of secreted protein acidic and rich in cysteine (SPARC) in pancreatic ductal adenocarcinoma (PDAC) patients after curative resection have not been clarified. We investigated the correlations between the SPARC expression and the postoperative prognosis.

Methods: We retrospectively analyzed the clinical data from consecutive patients who underwent curative resection for pancreatic cancer in our institution from 2005 to 2014. Stromal SPARC expression was analyzed by immunohistochemistry on tumor tissue microarrays (TMAs) from the patients.

Results: A total of 179 patients were enrolled to this study. The median follow-up period of the present study was 62.1 months. Seventy patients had positive SPARC expression (39.1%). There were no significant differences between the positive SPARC-positive group and the SPARC-negative group. In the survival analysis, there was a significant difference between the SPARC-positive and SPARC-negative groups in the 5-year overall survival (OS) rates after surgery, which were 8.1% and 19.8%, respectively (p=0.0316). A univariate analysis showed that the SPARC expression, size of tumor, lymph node metastasis, and residual tumor were possible prognostic factors. A multivariate analysis showed that the SPARC expression (hazard ratio [HR]: 1.44, 95% confidence interval [CI]: 1.017-2.051), lymph node metastasis (HR: 2.019, 95% CI: 1.318-3.091), and residual tumor (HR: 1.648, 95% CI: 1.132-2.401) were independent prognostic factors.

Conclusions: The stromal SPARC expression in resectable pancreatic cancer patients might be useful as a prognostic marker.

Keywords: pancreatic cancer, secreted protein acidic and rich in cysteine, prognostic factor

Citation styles

APA

Murakawa, M., Aoyama, T., Miyagi, Y., Kobayashi, S., Ueno, M., Morimoto, M., Numata, M., Yamamoto, N., Tamagawa, H., Yukawa, N., Rino, Y., Masuda, M., Morinaga, S. (2019). The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection. Journal of Cancer, 10(3), 627-633. https://doi.org/10.7150/jca.28660.

ACS

Murakawa, M.; Aoyama, T.; Miyagi, Y.; Kobayashi, S.; Ueno, M.; Morimoto, M.; Numata, M.; Yamamoto, N.; Tamagawa, H.; Yukawa, N.; Rino, Y.; Masuda, M.; Morinaga, S. The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection. J. Cancer 2019, 10 (3), 627-633. DOI: 10.7150/jca.28660.

NLM

CSE

Murakawa M, Aoyama T, Miyagi Y, Kobayashi S, Ueno M, Morimoto M, Numata M, Yamamoto N, Tamagawa H, Yukawa N, Rino Y, Masuda M, Morinaga S. 2019. The impact of SPARC expression on the survival of pancreatic ductal adenocarcinoma patients after curative resection. J Cancer. 10(3):627-633.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.